Biopharma BD&L and search & evaluation teams are the front lines to identifying and advancing new assets and platforms that shape a company’s pipeline. Their work is diverse: from competitive benchmarking and program assessment to commercial forecasting — all while tracking the explosion of global pharmaceutical innovation.

In this webinar, we explored:

• Best practices of BD and search & evaluation teams in their workflows
• Industry shifts driving demand for in-licensed assets
• How AI augments BD teams to intelligently streamline key work:
  • Identify and prioritize the top assets worth pursuing
  • Develop competitive benchmarking and scientific assessment
  • Diligence assets and qualify their alignment with strategic priorities
  • Review more opportunities without increasing headcount
  • Evaluate assets from overseas without needing costly translation

Watch Yael Weiss, CEO at Mahzi Therapeutics, and Alok Tayi, PhD, CEO at Vibe Bio, as they discuss BD&L efficiency and evaluation